MDD (Medical Devices Directive) review: not a text set in stone
This article was originally published in Clinica
The review of the Medical Devices Directive and the Active Implantable Medical Devices Directive, the texts of which have recently been adopted by the European Council and Parliament, leave many issues unresolved, writes Amanda Maxwell. But there has been a deliberate policy to leave many matters to future deliberation to keep the texts live and relevant, as Clinica heard at the June 7-8 Management Forum meeting in London on The Revision of the Medical Device Directives. Central to the future management of the medical device Directive is the increased emphasis and powers on the procedures for make binding decisions through the Article 7 directive implementation committee.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.